查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1825953

2025年正子斷層掃描（PET）核子醫學全球市場報告

Positron Emission Tomography (PET) Nuclear Medicine Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，正子斷層掃描 (PET) 核子醫學市場規模迅速擴張，從 2024 年的 114.9 億美元成長到 2025 年的 131.6 億美元，複合年成長率為 14.5%。預測期內的成長歸因於心血管疾病盛行率的上升、醫療支出的增加、泌尿系統疾病盛行率的上升、老年人口的成長以及醫院數量的增加。

預計未來幾年正子斷層掃描 (PET) 核醫市場規模將快速成長，到 2029 年將達到 225.2 億美元，複合年成長率為 14.4%。預測期內的成長可歸因於研發投入的增加、對微創診斷技術的需求不斷成長、全球醫療保健基礎設施的擴展、對食品和藥品包裝的需求不斷成長以及癌症患病率的上升。預測期內的主要趨勢包括技術進步、多重模式診斷、人工智慧整合、數位 PET 系統和個人化醫療。

正子斷層掃描 (PET) 核子醫學是一種醫學影像技術，利用放射性物質來觀察和評估體內的代謝活動。此方法使用少量放射性物質（稱為放射性追蹤劑）來檢測細胞層面的變化，使醫生能夠在早期診斷疾病。

正子斷層掃描 (PET) 核子醫學的主要類型包括 F-18 和 RB-82。 F-18（氟-18）是 PET 影像中常用的放射性同位素。 F-18 可用於多種程序，包括診斷影像、單光子放射電腦斷層掃描、治療性介入、BETA 和 α 射線治療以及近距離放射治療。 F-18 常用於腫瘤學、心臟病學和神經病學等領域。醫院、診斷中心和研究機構是 PET 核子醫學的主要最終使用者。

2025 年春季美國突然提高關稅以及由此引發的貿易摩擦對醫療保健產業產生了重大影響，尤其是基本醫療設備、診斷設備和藥品的供應。醫院和醫療保健提供者正努力應對進口手術器械、診斷影像系統以及注射器和導管等消耗品成本的上漲，其中許多產品的國內替代品有限。這些不斷上漲的成本使醫療保健預算捉襟見肘，導致一些醫療機構推遲設備升級或將增加的費用轉嫁給患者。此外，原料和零件的關稅擾亂了關鍵藥品和醫療設備的生產，導致供應鏈延遲。作為應對措施，該行業正在採用多樣化的籌資策略，盡可能擴大本地生產，並遊說對關鍵醫療產品免關稅。

本研究報告是商業研究公司（The Business Research Company）新報告系列的一部分，該系列提供正電子發射斷層掃描 (PET) 核醫市場統計數據，包括全球市場規模、各地區市場佔有率、各競爭對手的市場佔有率、正子斷層掃描 (PET) 核子醫學細分市場、市場趨勢和機遇，以及您在正子斷層掃描 (PET) 核子醫學細分市場、市場趨勢和機遇，以及您在正子斷層掃描 (PET) 斷層掃描行業取得成功所需的數據。本正子斷層掃描 (PET) 核子醫學市場研究報告對該行業的現狀和未來趨勢進行了詳細分析，為您提供所需的一切觀點。

未來五年14.4%的成長率預測比我們先前的預測略有下降，下降了0.2%。這一下降主要源自於美國與其他國家之間關稅的影響。貿易摩擦可能導致荷蘭和韓國開發的放射性藥物和檢測器模組價格上漲，阻礙先進正子斷層掃描(PET)影像在美國的普及，從而導致癌症診斷延誤和癌症治療成本上升。由於互惠關稅以及貿易緊張局勢和限制加劇對全球經濟和貿易的負面影響，其影響可能會更加廣泛。

預計未來幾年，慢性病盛行率的上升將推動正子斷層掃描 (PET) 核子醫學市場的成長。慢性病是一種長期健康狀況，通常持續三個月以上，需要持續的醫療照護或限制日常活動。導致慢性病盛行率上升的因素包括老化、久坐不動的生活方式、不良飲食和環境風險。 PET 核子醫學透過提供先進的影像診斷技術，促進慢性病的早期發現、準確診斷和持續監測，在慢性病管理中發揮關鍵作用。例如，2024 年 2 月，總部位於瑞士的政府間組織世界衛生組織 (WHO) 報告稱，2022 年將新增約 2,000 萬例癌症病例，並有 970 萬人死於癌症。此外，預計到 2050 年，新增癌症患者數量將超過 3,500 萬，比 2022 年的數字增加 77%。因此，慢性病盛行率的上升正在推動 PET 核醫市場的擴張。

PET核醫學領域的主要企業正專注於開發技術先進的產品，例如PET切片掃描儀，它可以提供代謝活動的高解析度影像。 PET切片掃描儀是一種醫學影像診斷設備，它將正子斷層掃描（PET）與先進的計算技術相結合，產生體內代謝過程的詳細截面影像，有助於檢測和監測疾病，尤其是癌症。例如，2024年7月，美國核子醫學公司Positron Corporation推出了NeuSight PET-CT 3D64切片掃描儀。這款創新掃描儀在成像和診斷準確性方面樹立了新的標準，將最尖端科技與患者舒適度和操作效率融為一體。它徹底改變了心臟PET成像，以極具吸引力的價格分佈提供了卓越的價值和性能，使其適用於心臟病學和腫瘤學的臨床研究。憑藉先進的數據收集和創新的識別技術，NeuSight PET-CT提高了掃描速度和準確性，為各種分子成像應用中的心臟、腫瘤和大腦研究提供全面的解剖和功能成像。

2023年2月，美國放射性藥物公司Lantheus Holdings Inc.收購了Cerveau Technologies Inc.，收購金額未揭露。此次收購將Lantheus的成長策略擴展，使其放射性藥物成像產品線涵阿茲海默症最常用的Tau蛋白正子斷層掃描(PET)顯像劑。此外，與眾多學術機構和製藥公司的夥伴關係也將增強其產品組合。 Cerveau Technologies Inc.專注於提供F-18標記的正子斷層掃描(PET)顯像劑，標靶治療與阿茲海默症相關的Tau蛋白纏結。

正子斷層掃描 (PET) 核子醫學市場涵蓋放射性示蹤劑、劑量校準設備、注射系統、病患監測系統和模擬工具的銷售。該市場的價值指的是“出廠價”，即商品製造商或生產商銷售給其他營業單位（包括下游製造商、批發商、經銷商和零售商）或直接銷售給最終客戶的商品價值。該市場中的商品價值還包括商品製造商銷售的任何相關服務。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通膨、地緣政治、貿易戰和關稅，以及新冠疫情和復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球正子斷層掃描 (PET) 核子醫學：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
  • 最終用途產業分析
  • 全球正子斷層掃描（PET）核子醫學市場：成長率分析
  • 全球正子斷層掃描 (PET) 核子醫學市場表現：規模與成長，2019-2024 年
  • 全球正子斷層掃描 (PET) 核子醫學市場預測：2024-2029 年及 2034 年規模與成長
  • 全球正子斷層掃描 (PET) 核子醫學：總目標市場 (TAM)

第6章 市場細分

  • 全球正子斷層掃描 (PET) 核子醫學市場：按類型、性能和預測，2019-2024 年、2024-2029 年、2034 年
  • F-18
  • Rb-82
  • 其他類型
  • 全球正子斷層掃描 (PET) 核子醫學市場（按程序、性能和預測），2019-2024 年、2024-2029 年、2034 年
  • 診斷程序
  • 單光子發射電腦斷層掃描
  • 正子斷層掃描
  • 治療程序
  • BETA 放射體程序
  • 阿爾法發射程序
  • 全球正子斷層掃描 (PET) 核子醫學市場：應用、績效及預測（2019-2024 年、2024-2029 年及 2034 年）
  • 腫瘤學
  • 心臟病學
  • 神經病學
  • 其他用途
  • 全球正子斷層掃描 (PET) 核子醫學市場：按最終用戶、績效和預測，2019-2024 年、2024-2029 年、2034 年
  • 醫院
  • 診斷中心
  • 研究機構
  • 全球正子斷層掃描 (PET) 核子醫學市場：按 F-18（氟-18）細分、類型、效能和預測，2019-2024 年、2024-2029 年、2034 年
  • F-18 FDG（氟脫氧葡萄糖）
  • F-18 NaF（氟化鈉）
  • F-18氟膽鹼
  • 全球正子斷層掃描 (PET) 核子醫學市場：按 Rb-82（銣-82）細分，類型、性能和預測，2019-2024 年、2024-2029 年、2034 年
  • Rb-82 用於心肌灌注顯像
  • 用於心臟PET壓力測試Rb-82
  • Rb-82 在其他心臟應用中
  • 全球正子斷層掃描 (PET) 核子醫學市場：按類型、實際和預測細分，2019-2024 年、2024-2029 年、2034 年
  • C-11（碳11）
  • N-13（氮13）
  • O-15（氧15）
  • Ga-68（鎵-68）

第7章 區域和國家分析

  • 全球正子斷層掃描 (PET) 核子醫學市場：區域分析、預測（2019-2024 年、2024-2029 年及 2034 年）
  • 全球正子斷層掃描 (PET) 核子醫學市場：國家、績效及預測（2019-2024 年、2024-2029 年及 2034 年）

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章：澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章：西歐市場

第16章英國市場

第17章：德國市場

第18章：法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章：俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章：競爭格局與公司概況

  • 正子斷層掃描（PET）核子醫學市場：競爭格局
  • 正子斷層掃描（PET）核子醫學市場：公司簡介
    • Cardinal Health Overview, Products and Services, Strategy and Financial Analysis
    • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • Medtronic plc Overview, Products and Services, Strategy and Financial Analysis
    • Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
    • Fujifilm Holdings Corporation Overview, Products and Services, Strategy and Financial Analysis

第31章：其他領先和創新企業

  • Stryker Corporation
  • GE HealthCare Technologies Inc.
  • Koninklijke Philips NV
  • Agfa HealthCare NV
  • Scripps Health
  • Shimadzu Corporation
  • Jubilant DraxImage Inc.
  • Neusoft Medical Systems Co. Ltd.
  • Toshiba America Medical Systems Inc.
  • Lantheus Holdings Inc.
  • Advanced Accelerator Applications
  • Bruker Corporation
  • Eckert & Ziegler Strahlen-und Medizintechnik AG
  • Canon Medical Systems Corporation
  • Digirad Corporation

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第 35 章：高潛力市場國家、細分市場與策略

  • 2029年正子斷層掃描（PET）核子醫學市場：提供新機會的國家
  • 2029年正子斷層掃描（PET）核子醫學市場：細分領域帶來新機會
  • 正子斷層掃描 (PET) 核子醫學市場 2029 年：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第36章 附錄

簡介目錄
Product Code: r32169u

Positron Emission Tomography (PET) nuclear medicine is a medical imaging technique that utilizes radioactive materials to visualize and evaluate metabolic activities within the body. This method employs a small amount of radioactive material known as a radiotracer to detect changes at the cellular level, enabling physicians to diagnose diseases at an early stage.

The main types of positron emission tomography (PET) nuclear medicines include F-18, RB-82, and others. F-18, or fluorine-18, is a radioactive isotope frequently used in PET imaging. It is employed in various procedures, including diagnostic imaging, single photon emission computed tomography, therapeutic interventions, beta and alpha emitter procedures, and brachytherapy. F-18 is commonly applied in fields such as oncology, cardiology, and neurology. The primary end users of PET nuclear medicine include hospitals, diagnostic centers, and research institutions.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The positron emission tomography (PET) nuclear medicine market research report is one of a series of new reports from The Business Research Company that provides positron emission tomography (PET) nuclear medicine market statistics, including positron emission tomography (PET) nuclear medicine industry global market size, regional shares, competitors with a positron emission tomography (PET) nuclear medicine market share, detailed positron emission tomography (PET) nuclear medicine market segments, market trends and opportunities, and any further data you may need to thrive in the positron emission tomography (PET) nuclear medicine industry. This positron emission tomography (PET) nuclear medicine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The positron emission tomography (pet) nuclear medicine market size has grown rapidly in recent years. It will grow from $11.49 billion in 2024 to $13.16 billion in 2025 at a compound annual growth rate (CAGR) of 14.5%. The growth in the historic period can be attributed to increasing prevalence of cardiovascular diseases, increasing healthcare expenditures, increasing prevalence of urological diseases, increasing geriatric population, and increasing number of hospitals.

The positron emission tomography (pet) nuclear medicine market size is expected to see rapid growth in the next few years. It will grow to $22.52 billion in 2029 at a compound annual growth rate (CAGR) of 14.4%. The growth in the forecast period can be attributed to increasing investment in research and development, rising demand for minimally invasive diagnostic techniques, expanding global healthcare infrastructure, increasing demand for food and pharmaceutical packaging, and rising prevalence of cancer. Major trends in the forecast period include technological advancements, multi-modality diagnosis, artificial intelligence integration, digital PET systems, and personalized medicine.

The forecast of 14.4% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. adoption of advanced Positron Emission Tomography imaging by inflating prices of radiopharmaceuticals and detector modules developed in the Netherlands and South Korea, resulting in delayed cancer diagnostics and higher oncology costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising incidence of chronic diseases is projected to drive the growth of the positron emission tomography (PET) nuclear medicine market in the coming years. Chronic diseases are long-term health conditions that usually persist for three months or longer, often requiring continuous medical care or limiting daily activities. Factors contributing to the increase in chronic diseases include an aging population, sedentary lifestyles, poor dietary habits, and environmental risks. PET nuclear medicine plays a crucial role in managing chronic diseases by providing advanced imaging techniques that facilitate early detection, accurate diagnosis, and ongoing monitoring of these conditions. For example, in February 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental agency, reported that approximately 20 million new cancer cases and 9.7 million cancer-related deaths occurred in 2022. Furthermore, it is anticipated that by 2050, new cancer cases will surpass 35 million, marking a 77% increase from the 2022 figures. Thus, the rising prevalence of chronic diseases is driving the expansion of the PET nuclear medicine market.

Leading companies in the PET nuclear medicine sector are focusing on developing technologically advanced products, such as PET slice scanners, to deliver high-resolution images of metabolic activity. A PET slice scanner is a medical imaging device that integrates positron emission tomography (PET) with advanced computational techniques to generate detailed cross-sectional images of metabolic processes in the body, aiding in the detection and monitoring of diseases, especially cancer. For instance, in July 2024, Positron Corporation, a U.S.-based nuclear medicine company, introduced the NeuSight PET-CT 3D 64-slice scanner. This innovative scanner sets new standards for imaging and diagnostic accuracy, merging cutting-edge technology with patient comfort and operational efficiency. It aims to revolutionize cardiac PET imaging, providing exceptional value and performance at an attractive price point, making it suitable for cardiology and oncology clinical studies. With advanced data acquisition and innovative identification technology, the NeuSight PET-CT enhances both scanning speed and accuracy, offering comprehensive anatomical and functional imaging for heart, tumor, and brain studies across various molecular imaging applications.

In February 2023, Lantheus Holdings Inc., a U.S.-based radiopharmaceutical company, acquired Cerveau Technologies Inc. for an undisclosed sum. This acquisition supports Lantheus's growth strategy by broadening its pipeline of radiopharmaceutical diagnostic imaging agents to include the most commonly used Tau PET imaging agent for Alzheimer's disease. Additionally, it strengthens its portfolio with numerous academic collaborations and pharmaceutical partnerships. Cerveau Technologies Inc. specializes in providing F-18 labeled positron emission tomography imaging agents that target Tau tangles associated with Alzheimer's disease.

Major companies operating in the positron emission tomography (PET) nuclear medicine market are Cardinal Health, Bayer AG, Medtronic plc, Siemens Healthineers AG, Fujifilm Holdings Corporation, Stryker Corporation, GE HealthCare Technologies Inc., Koninklijke Philips N.V., Agfa HealthCare NV, Scripps Health, Shimadzu Corporation, Jubilant DraxImage Inc., Neusoft Medical Systems Co. Ltd., Toshiba America Medical Systems Inc., Lantheus Holdings Inc., Advanced Accelerator Applications, Bruker Corporation, Eckert & Ziegler Strahlen- und Medizintechnik AG, Canon Medical Systems Corporation, Digirad Corporation, NorthStar Medical Radioisotopes LLC, Mediso Medical Imaging Systems Ltd.

North America was the largest region in the positron emission tomography (PET) nuclear medicine market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the positron emission tomography (PET) nuclear medicine marker report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the positron emission tomography (PET) nuclear medicine marker report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The positron emission tomography (PET) nuclear medicine market consists of sales of radiotracers, dose calibrators, injection systems, patient monitoring systems and simulation tools. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Positron Emission Tomography (PET) Nuclear Medicine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on positron emission tomography (pet) nuclear medicine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for positron emission tomography (pet) nuclear medicine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The positron emission tomography (pet) nuclear medicine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: F-18; Rb-82; Other Types
  • 2) By Procedure: Diagnostic Procedures; Single Photon Emission Computed Tomography Procedures; Positron Emission Tomography Procedures; Therapeutic Procedures; Beta Emitter Procedures; Alpha Emitter Procedures; Brachytherapy Procedures
  • 3) By Application: Oncology; Cardiology; Neurology; Other Applications
  • 4) By End User: Hospitals; Diagnostic Centers; Research Institutes
  • Subsegments:
  • 1) By F-18 (Fluorine-18): F-18 FDG (Fluorodeoxyglucose); F-18 NaF (Sodium Fluoride); F-18 Fluorocholine
  • 2) By Rb-82 (Rubidium-82): Rb-82 for Myocardial Perfusion Imaging; Rb-82 for Cardiac PET Stress Testing; Rb-82 for Other Cardiac Applications
  • 3) By Other Types: C-11 (Carbon-11); N-13 (Nitrogen-13); O-15 (Oxygen-15); Ga-68 (Gallium-68)
  • Companies Mentioned: Cardinal Health; Bayer AG; Medtronic plc; Siemens Healthineers AG; Fujifilm Holdings Corporation; Stryker Corporation; GE HealthCare Technologies Inc.; Koninklijke Philips N.V.; Agfa HealthCare NV; Scripps Health; Shimadzu Corporation; Jubilant DraxImage Inc.; Neusoft Medical Systems Co. Ltd.; Toshiba America Medical Systems Inc.; Lantheus Holdings Inc.; Advanced Accelerator Applications; Bruker Corporation; Eckert & Ziegler Strahlen- und Medizintechnik AG; Canon Medical Systems Corporation; Digirad Corporation; NorthStar Medical Radioisotopes LLC; Mediso Medical Imaging Systems Ltd.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Positron Emission Tomography (PET) Nuclear Medicine Market Characteristics

3. Positron Emission Tomography (PET) Nuclear Medicine Market Trends And Strategies

4. Positron Emission Tomography (PET) Nuclear Medicine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Positron Emission Tomography (PET) Nuclear Medicine Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Positron Emission Tomography (PET) Nuclear Medicine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Positron Emission Tomography (PET) Nuclear Medicine Market Growth Rate Analysis
  • 5.4. Global Positron Emission Tomography (PET) Nuclear Medicine Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Positron Emission Tomography (PET) Nuclear Medicine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Positron Emission Tomography (PET) Nuclear Medicine Total Addressable Market (TAM)

6. Positron Emission Tomography (PET) Nuclear Medicine Market Segmentation

  • 6.1. Global Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • F-18
  • Rb-82
  • Other Types
  • 6.2. Global Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Diagnostic Procedures
  • Single Photon Emission Computed Tomography Procedures
  • Positron Emission Tomography Procedures
  • Therapeutic Procedures
  • Beta Emitter Procedures
  • Alpha Emitter Procedures
  • 6.3. Global Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oncology
  • Cardiology
  • Neurology
  • Other Applications
  • 6.4. Global Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Diagnostic Centers
  • Research Institutes
  • 6.5. Global Positron Emission Tomography (PET) Nuclear Medicine Market, Sub-Segmentation Of F-18 (Fluorine-18), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • F-18 FDG (Fluorodeoxyglucose)
  • F-18 NaF (Sodium Fluoride)
  • F-18 Fluorocholine
  • 6.6. Global Positron Emission Tomography (PET) Nuclear Medicine Market, Sub-Segmentation Of Rb-82 (Rubidium-82), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Rb-82 for Myocardial Perfusion Imaging
  • Rb-82 for Cardiac PET Stress Testing
  • Rb-82 for Other Cardiac Applications
  • 6.7. Global Positron Emission Tomography (PET) Nuclear Medicine Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • C-11 (Carbon-11)
  • N-13 (Nitrogen-13)
  • O-15 (Oxygen-15)
  • Ga-68 (Gallium-68)

7. Positron Emission Tomography (PET) Nuclear Medicine Market Regional And Country Analysis

  • 7.1. Global Positron Emission Tomography (PET) Nuclear Medicine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Positron Emission Tomography (PET) Nuclear Medicine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Positron Emission Tomography (PET) Nuclear Medicine Market

  • 8.1. Asia-Pacific Positron Emission Tomography (PET) Nuclear Medicine Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Positron Emission Tomography (PET) Nuclear Medicine Market

  • 9.1. China Positron Emission Tomography (PET) Nuclear Medicine Market Overview
  • 9.2. China Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Positron Emission Tomography (PET) Nuclear Medicine Market

  • 10.1. India Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Positron Emission Tomography (PET) Nuclear Medicine Market

  • 11.1. Japan Positron Emission Tomography (PET) Nuclear Medicine Market Overview
  • 11.2. Japan Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Positron Emission Tomography (PET) Nuclear Medicine Market

  • 12.1. Australia Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Positron Emission Tomography (PET) Nuclear Medicine Market

  • 13.1. Indonesia Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Positron Emission Tomography (PET) Nuclear Medicine Market

  • 14.1. South Korea Positron Emission Tomography (PET) Nuclear Medicine Market Overview
  • 14.2. South Korea Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Positron Emission Tomography (PET) Nuclear Medicine Market

  • 15.1. Western Europe Positron Emission Tomography (PET) Nuclear Medicine Market Overview
  • 15.2. Western Europe Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Positron Emission Tomography (PET) Nuclear Medicine Market

  • 16.1. UK Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Positron Emission Tomography (PET) Nuclear Medicine Market

  • 17.1. Germany Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Positron Emission Tomography (PET) Nuclear Medicine Market

  • 18.1. France Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Positron Emission Tomography (PET) Nuclear Medicine Market

  • 19.1. Italy Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Positron Emission Tomography (PET) Nuclear Medicine Market

  • 20.1. Spain Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Positron Emission Tomography (PET) Nuclear Medicine Market

  • 21.1. Eastern Europe Positron Emission Tomography (PET) Nuclear Medicine Market Overview
  • 21.2. Eastern Europe Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Positron Emission Tomography (PET) Nuclear Medicine Market

  • 22.1. Russia Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Positron Emission Tomography (PET) Nuclear Medicine Market

  • 23.1. North America Positron Emission Tomography (PET) Nuclear Medicine Market Overview
  • 23.2. North America Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Positron Emission Tomography (PET) Nuclear Medicine Market

  • 24.1. USA Positron Emission Tomography (PET) Nuclear Medicine Market Overview
  • 24.2. USA Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Positron Emission Tomography (PET) Nuclear Medicine Market

  • 25.1. Canada Positron Emission Tomography (PET) Nuclear Medicine Market Overview
  • 25.2. Canada Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Positron Emission Tomography (PET) Nuclear Medicine Market

  • 26.1. South America Positron Emission Tomography (PET) Nuclear Medicine Market Overview
  • 26.2. South America Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Positron Emission Tomography (PET) Nuclear Medicine Market

  • 27.1. Brazil Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Positron Emission Tomography (PET) Nuclear Medicine Market

  • 28.1. Middle East Positron Emission Tomography (PET) Nuclear Medicine Market Overview
  • 28.2. Middle East Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Positron Emission Tomography (PET) Nuclear Medicine Market

  • 29.1. Africa Positron Emission Tomography (PET) Nuclear Medicine Market Overview
  • 29.2. Africa Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Procedure, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Positron Emission Tomography (PET) Nuclear Medicine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Positron Emission Tomography (PET) Nuclear Medicine Market Competitive Landscape And Company Profiles

  • 30.1. Positron Emission Tomography (PET) Nuclear Medicine Market Competitive Landscape
  • 30.2. Positron Emission Tomography (PET) Nuclear Medicine Market Company Profiles
    • 30.2.1. Cardinal Health Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Medtronic plc Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Fujifilm Holdings Corporation Overview, Products and Services, Strategy and Financial Analysis

31. Positron Emission Tomography (PET) Nuclear Medicine Market Other Major And Innovative Companies

  • 31.1. Stryker Corporation
  • 31.2. GE HealthCare Technologies Inc.
  • 31.3. Koninklijke Philips N.V.
  • 31.4. Agfa HealthCare NV
  • 31.5. Scripps Health
  • 31.6. Shimadzu Corporation
  • 31.7. Jubilant DraxImage Inc.
  • 31.8. Neusoft Medical Systems Co. Ltd.
  • 31.9. Toshiba America Medical Systems Inc.
  • 31.10. Lantheus Holdings Inc.
  • 31.11. Advanced Accelerator Applications
  • 31.12. Bruker Corporation
  • 31.13. Eckert & Ziegler Strahlen- und Medizintechnik AG
  • 31.14. Canon Medical Systems Corporation
  • 31.15. Digirad Corporation

32. Global Positron Emission Tomography (PET) Nuclear Medicine Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Positron Emission Tomography (PET) Nuclear Medicine Market

34. Recent Developments In The Positron Emission Tomography (PET) Nuclear Medicine Market

35. Positron Emission Tomography (PET) Nuclear Medicine Market High Potential Countries, Segments and Strategies

  • 35.1 Positron Emission Tomography (PET) Nuclear Medicine Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Positron Emission Tomography (PET) Nuclear Medicine Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Positron Emission Tomography (PET) Nuclear Medicine Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer